US Drug Recall Register
Class II · Moderate risk Terminated Initiated Sep 26, 2012 (14 years ago)

Betamethasone Sodium Phosphate 6 mg/mL P Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

What was recalled

Betamethasone Sodium Phosphate 6 mg/mL P Injection, Betamethasone Sodium Phosphate 6 mg/mL PF Injection, Betamethasone Sodium Phosphate 8 mg/mL PF Injection, Betamethasone Sodium Phosphate 12 mg/mL PF Injection, manufactured by New England Compounding Center, Framingham, MA

Recalling firm
New England Compounding Center
Origin
MA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-113-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Betamethasone recalls

See all
Class II · Moderate risk Ongoing

Betamethasone Dipropionate Ointment USP

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

McKesson Corporation dba McKesson Drug Company NDC 63739-996-65 D-0850-2022
Class II · Moderate risk Terminated

Celestone Soluspan

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0085-4320-01 D-1089-2022
Class II · Moderate risk Terminated

Betamethasone Dipropionate Cream USP

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0168-0055-46 D-1028-2022
Class II · Moderate risk Terminated

Betamethasone Dipropionate Lotion USP

Reason cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Teligent Pharma, Inc. NDC 52565-023-29 D-0669-2022
Class III · Low risk Terminated

Clotrimazole and Betamethasone Dipropionate Cream USP

Reason Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample

Taro Pharmaceuticals U.S.A., Inc. NDC 51672-4048-1 D-0727-2022